UH2CA248974
Cooperative Agreement
Overview
Grant Description
Fetal Origins of Testicular Cancer: A Metabolomics Study in Newborns - Project Summary/Abstract
Testicular cancer, mainly comprised of testicular germ cell tumors (TGCT), is the most common solid tumor among adolescent and young adult males. Its incidence has increased dramatically during the past 40 years worldwide and in the US. Compared to other racial/ethnic groups, Latinos experience the highest increase in both incidence and mortality rates since 2000, leading to major health disparities.
In addition, the disease burden is high in terms of serious life-long treatment-related complications in cancer survivors, and years of potential life lost in this young population. As a result, etiologic and prevention research of TGCT is of high public health importance.
The rapid increase in TGCT incidence suggests that environment plays an important etiology role, yet no environmental risk factors to date have been identified. Some reports have suggested that exposure to endocrine disrupting chemicals during pregnancy may be associated with future risk of TGCT, but no human studies have directly tested this hypothesis.
TGCT is believed to have fetal origin and to develop from an initiating event occurring in utero, resulting in a precursor lesion that progresses to TGCT in nearly all cases. The difficulty in obtaining prospectively collected (pre-diagnosis) biological specimens from this critical period of development (prenatal) has posed a major limitation to the identification of environmental risk factors.
The field of "exposomics" studies all relevant chemical exposures; metabolomics platforms estimate the "internal" environment of an individual that may identify both exogenous exposures involved in disease development. By leveraging newborn dried blood spots archived by the state of California on all infants born in the state, we will conduct a detailed "exposomic" analysis of fetal life that could identify environmental triggers in TGCT etiology.
Using an untargeted analysis which measures thousands of exogenous and endogenous metabolites simultaneously permits us to make inference on fetal exposure and in utero metabolism and biologic response. Additionally, we will apply novel statistical methods that simultaneously examine thousands of biochemical signatures.
Using a semi-targeted approach, we will also test the hypothesis that birth levels of phthalates, an endocrine disruptor associated with male genital anomalies, is associated with TGCT risk.
Our proposed study is novel in that it overcomes conceptual and methodological challenges that have hindered previous studies of the fetal origin of TGCT (especially access to blood specimens collected at birth to characterize the fetal/neonatal periods); utilizes untargeted and semi-targeted approaches to identify a large number relevant biochemical signatures and to test current hypotheses in TGCT environmental epidemiology; and uses novel statistical methods to examine two and three-way interactions without the need for large sample sizes.
Our large and ethnically diverse California-based study population will provide the opportunity to fill important knowledge gaps about the factors contributing to TGCT.
Testicular cancer, mainly comprised of testicular germ cell tumors (TGCT), is the most common solid tumor among adolescent and young adult males. Its incidence has increased dramatically during the past 40 years worldwide and in the US. Compared to other racial/ethnic groups, Latinos experience the highest increase in both incidence and mortality rates since 2000, leading to major health disparities.
In addition, the disease burden is high in terms of serious life-long treatment-related complications in cancer survivors, and years of potential life lost in this young population. As a result, etiologic and prevention research of TGCT is of high public health importance.
The rapid increase in TGCT incidence suggests that environment plays an important etiology role, yet no environmental risk factors to date have been identified. Some reports have suggested that exposure to endocrine disrupting chemicals during pregnancy may be associated with future risk of TGCT, but no human studies have directly tested this hypothesis.
TGCT is believed to have fetal origin and to develop from an initiating event occurring in utero, resulting in a precursor lesion that progresses to TGCT in nearly all cases. The difficulty in obtaining prospectively collected (pre-diagnosis) biological specimens from this critical period of development (prenatal) has posed a major limitation to the identification of environmental risk factors.
The field of "exposomics" studies all relevant chemical exposures; metabolomics platforms estimate the "internal" environment of an individual that may identify both exogenous exposures involved in disease development. By leveraging newborn dried blood spots archived by the state of California on all infants born in the state, we will conduct a detailed "exposomic" analysis of fetal life that could identify environmental triggers in TGCT etiology.
Using an untargeted analysis which measures thousands of exogenous and endogenous metabolites simultaneously permits us to make inference on fetal exposure and in utero metabolism and biologic response. Additionally, we will apply novel statistical methods that simultaneously examine thousands of biochemical signatures.
Using a semi-targeted approach, we will also test the hypothesis that birth levels of phthalates, an endocrine disruptor associated with male genital anomalies, is associated with TGCT risk.
Our proposed study is novel in that it overcomes conceptual and methodological challenges that have hindered previous studies of the fetal origin of TGCT (especially access to blood specimens collected at birth to characterize the fetal/neonatal periods); utilizes untargeted and semi-targeted approaches to identify a large number relevant biochemical signatures and to test current hypotheses in TGCT environmental epidemiology; and uses novel statistical methods to examine two and three-way interactions without the need for large sample sizes.
Our large and ethnically diverse California-based study population will provide the opportunity to fill important knowledge gaps about the factors contributing to TGCT.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
California
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/23 to 05/31/24 and the total obligations have increased 77% from $244,799 to $434,198.
Regents Of The University Of California was awarded
Fetal Origins of Testicular Cancer: A Metabolomics Study in Newborns
Cooperative Agreement UH2CA248974
worth $434,198
from National Cancer Institute in June 2021 with work to be completed primarily in California United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.393 Cancer Cause and Prevention Research.
The Cooperative Agreement was awarded through grant opportunity Early-life Factors and Cancer Development Later in Life (R21 - Clinical Trial Not Allowed).
Status
(Complete)
Last Modified 9/5/24
Period of Performance
6/10/21
Start Date
5/31/24
End Date
Funding Split
$434.2K
Federal Obligation
$0.0
Non-Federal Obligation
$434.2K
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for UH2CA248974
Transaction History
Modifications to UH2CA248974
Additional Detail
Award ID FAIN
UH2CA248974
SAI Number
UH2CA248974-292842382
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
GS3YEVSS12N6
Awardee CAGE
50853
Performance District
CA-90
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $189,399 | 100% |
Modified: 9/5/24